Does the circulating level of myosin-11 accurately detect patients with atherosclerotic cardiovascular disease risk?
Circulating myosin-11 levels measured by a novel ELISA show high diagnostic accuracy for identifying patients with ischemic heart disease and those at risk for ASCVD.
Atherosclerosis leads to severe clinical complications, and biomarkers for asymptomatic atherosclerosis are desired. Plasma levels of myosin-11 have been reported to increase in patients with symptomatic atherosclerosis. To investigate the association between circulating myosin-11 levels and atherosclerotic cardiovascular disease (ASCVD) risk in patients without symptomatic atherosclerosis, this study recruited 161 participants: 80 patients with ASCVD risk, 50 patients with ischemic heart disease (IHD), and 31 control participants (Controls). We developed an ELISA that consists of rat monoclonal antibodies specific for the coiled-coil domain of myosin-11. Myosin-11 levels were highest in the IHD group, followed by the ASCVD risk group. The area under the receiver-operating characteristic curve of myosin-11 was 0.980 for IHD versus Controls and 0.874 for ASCVD risk versus Controls. The association between myosin-11 levels and hypertension remained significant after multivariate logistic regression analysis. Myosin-11 levels may be a biomarker for stratification of asymptomatic individuals with ASCVD risk.
Takahashi et al. (Thu,) studied this question.